Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972638 | 0.93 | CYP3A4 (0.55) | PRCPCYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2685422 | 0.91 | PRCP (0.59) | PRCPCYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL5992658 | 0.89 | HPGDS (0.49) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL5992962 | 0.88 | PRCP (0.58) | PRCPCYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL5991412 | 0.86 | PRCP (0.48) | PRCPCYP3A4CYP2C9NR1I2ABCB11 | |
| SCHEMBL2706110 | 0.85 | CYP3A4 (0.58) | PRCPCYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL753302 | 0.84 | CYP3A4 (0.60) | PRCPCYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL11910995 | 0.84 | CYP3A4 (0.60) | PRCPCYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL15765637 | 0.83 | CYP3A4 (0.73) | PRCPCYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL13223842 | 0.83 | PRCP (0.55) | PRCPCYP3A4CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2012083164-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | PRCP 816/4885CYP3A4 1792/4885CYP2C9 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.